Sumitomo Chemical Advanced Medical

Tokyo, JP

Hybrid — also manufactures internal programs

Oligonucleotide Cell Therapy

Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15

63.0

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press

Quick Facts: Sumitomo Chemical Advanced Medical

Signal Score: 63.0/100 (as of 2026-03-15)
Quality Compliance: Assessment pending
Headquarters: Tokyo, JP
Modalities: Oligonucleotide, Cell Therapy
Active CGT Programs: No ClinicalTrials.gov matches confirmed
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CGT manufacturing intelligence platform

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesOligonucleotide, Cell Therapy

No clinical trial matches found for this manufacturer

Operational score requires ClinicalTrials.gov data

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Subsidiary of Sumitomo Chemical

SEC FilingsParent: Sumitomo Chemical

Parent company: Sumitomo Chemical

Financial assessment: 68.0/100

Capacity

1 CGT manufacturing site

1 CGT manufacturing site: Tokyo, JP

Modalities: Oligonucleotide, Cell Therapy

Capacity assessment: 58.0/100

Represent this organization? Contact us to verify or update this profile.

See all CDMOs in:

Oligonucleotide CDMOs → Cell Therapy CDMOs →